For the quarter ended September 2025, Conmed (CNMD) reported revenue of $337.93 million, up 6.7% over the same period last year. EPS came in at $1.08, compared to $1.05 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $336.52 million, representing a surprise of +0.42%. The company delivered an EPS surprise of +2.86%, with the consensus EPS estimate being $1.05.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Conmed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- International: $143.9 million compared to the $148.63 million average estimate based on two analysts. The reported number represents a change of +7.8% year over year.
- Geographic Revenue- Domestic: $194 million versus $187.89 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.9% change.
- Net Sales- Single-use Products: $289.2 million versus the two-analyst average estimate of $288.97 million. The reported number represents a year-over-year change of +6.8%.
- Net Sales- General Surgery: $199.7 million compared to the $200.27 million average estimate based on two analysts. The reported number represents a change of +7.3% year over year.
- Net Sales- Orthopedic Surgery: $138.2 million versus the two-analyst average estimate of $136.24 million. The reported number represents a year-over-year change of +5.9%.
- Net Sales- Capital Products: $48.7 million versus $47.55 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.1% change.
View all Key Company Metrics for Conmed here>>>
Shares of Conmed have returned -0.4% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CONMED Corporation (CNMD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
